SILVER SPRING, Md. (October 24, 2013)--An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from a panel of government experts.
The experts say the medication should be approved to treat patients infected with the liver-destroying virus.
All 19 members of a panel of Food and Drug Administration advisers voted in favor of approving J&J's simeprevir, a daily pill designed to eliminate the most common form of hepatitis C.
The FDA is not required to follow the group's recommendation, although it often does.
A decision on the drug is expected next month.
More than 3 million people in the U.S. have hepatitis C, a blood-borne disease that causes liver damage and is blamed for 15,000 deaths a year.
J&J is one of a half-dozen companies working to develop more effective treatments for the virus.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.